IL6 and breast carcinoma: The breast cancer cell lines, MCF-7 and MDA-MB-468, showed little or no response to IL-6, with an apparent dose-dependent increase in outliers, indicating that a small subset of the cells respond to IL-6 to the same extent as Cal33 or 686LN cells and with the same sensitivity as Cal33 cells.